GlassScriptPhysician profile
Michelle Manias
NPI 1497240212
$5,120.66
in general payments reported to CMS, 2019-2025
52 companies · $2,168 in 2025
The $2,168 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.84 · 2022: $232 · 2023: $716 · 2024: $1,929 · 2025: $2,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,651 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,650.87 |
| Education | $162.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $524.54 | 2023-2025 | |
| Gilead Sciences, INC. | $482.32 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $300.58 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $286.84 | 2022-2025 | |
| Janssen Biotech, INC. | $252.19 | 2021-2025 | Talvey, Darzalex, Rybrevant |
| Glaxosmithkline, LLC. | $210.61 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $206.94 | 2024-2025 | |
| Lilly USA, LLC | $197.64 | 2021-2025 | Jaypirca, Verzenio |
| Abbvie INC. | $172.36 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $165.75 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Rigel Pharmaceuticals, INC. | $164.24 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Seagen INC. | $135.49 | 2023-2025 | Padcev, Tukysa |
| Astellas Pharma US INC | $127.87 | 2023-2025 | Xtandi, Padcev |
| Kite Pharma, INC. | $122.19 | 2024-2025 | Yescarta |
| Blueprint Medicines Corporation | $119.32 | 2023-2024 | Ayvakit |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Manias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.